SCHEMBL3971162

SCHEMBL3971162

Clc1ccc2c(Nc3ccccc3)nc(-c3ccccc3)nc2c1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 12/20 0.74
PDE5A O76074 5/20 0.74
MEN1 O00255 3/20 0.70
KMT2A Q03164 3/20 0.70
AURKA O14965 1/20 0.65
KDM4E B2RXH2 2/20 0.63
TGFBR1 P36897 2/20 0.63
TP53 P04637 3/20 0.62
MAPT P10636 3/20 0.62
POLB P06746 2/20 0.62
GAA P10253 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.59
MAPK14 Q16539 1/20 0.59
ALDH1A1 P00352 1/20 0.59
HPGD P15428 1/20 0.59
LMNA P02545 1/20 0.58
ABCB1 P08183 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3977614 0.91 ABCG2 (0.66) ABCG2PDE5AMEN1KMT2AAURKA
SCHEMBL15452767 0.88 ABCG2 (0.76) ABCG2PDE5AMEN1KMT2AAURKA
SCHEMBL4867505 0.85 ABCG2 (1.00) ABCG2PDE5AMEN1KMT2ATGFBR1
SCHEMBL1063103 0.83 ABCG2 (1.00) ABCG2PDE5AMEN1KMT2AKDM4E
SCHEMBL16404313 0.83 ABCG2 (0.74) ABCG2PDE5AMEN1KMT2AKDM4E
SCHEMBL3583464 0.81 ROCK2 (0.58) ABCG2PDE5AAURKAKDM4ETGFBR1
SCHEMBL16404289 0.81 ABCG2 (0.71) ABCG2PDE5AMEN1KMT2AKDM4E
SCHEMBL14474125 0.80 ABCG2 (0.65) ABCG2PDE5AKDM4ETGFBR1MAPT
SCHEMBL16404487 0.80 ABCG2 (0.76) ABCG2PDE5AMEN1KMT2AAURKA
SCHEMBL16404320 0.80 ABCG2 (0.65) ABCG2PDE5AMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8936840-B2 Retardation film, polarizing plate, liquid crystal display device, and compound Konica Minolta, Inc. (JP) 2015-01-20 US disclosed
US-8936840-B2 Retardation film, polarizing plate, liquid crystal display device, and compound Konica Minolta, Inc. (JP) 2015-01-20 US disclosed
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
CN-1474815-A 4-amino-quinazolines Ĭ��ר���ɷ����޹�˾ 2004-02-11 CN disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 ABCG2 119/4885PDE5A 2783/4885MEN1 3915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.